{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:52:43Z","timestamp":1791280363387,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Denosumab increases bone mineral density (BMD) in dialysis patients, but the effects on bone microarchitecture using high-resolution peripheral quantitative computed tomography (HRpQCT) and the response factors to treatment are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed, at a single center between 2014 and 2024, 19 consecutive patients on hemodialysis having a longitudinal HRpQCT monitoring at the distal tibia and radius. After excluding the presence of osteomalacia based on bone biopsies and ensuring well-controlled parathyroid hormone levels, nine patients with recent fractures were treated with denosumab. Changes in HRpQCT parameters observed over time were analyzed within the denosumab group and were compared to a group of a nontreated patients, using linear mixed models for repeated measures. Baseline histomorphometric parameters were analyzed as predictors of changes in HRpQCT parameters over time in denosumab-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median [maximum\u2013minimum] follow-up period of 2.1 [1.0\u20133.5] years, the nine denosumab-treated patients had a significant improvement of (i) bone volume-to-total volume ratio at the distal radius (+1.63% [95% confidence interval: 1.11\u20133.31] per year, P = .037) and tibia (+1.13% [0.10\u20132.28], P = .049), (ii) trabecular volumetric BMD at the distal radius (+1.58 [1.07\u20133.30], P = .039) and tibia (+0.95% [0.11\u20131.97], P = .039), (iii) trabecular number at the distal radius (+1.86% [0.45\u20133.28], P = .017), and (iv) trabecular separation at the distal radius (\u22121.83% [\u22123.16 to \u22120.50], P = .014). These changes were also significant when compared with those of the untreated group. Changes in cortical parameters did not change significantly over time. At most, changes in trabecular volumetric BMD at the radius were negatively associated with osteoid volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab improves HRpQCT trabecular bone parameters without significant effect on cortical parameters in dialysis patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag182","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:26:21Z","timestamp":1789755981000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of denosumab on bone high-resolution peripheral quantitative computed tomography in hemodialysis patients: a retrospective longitudinal observational study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-7110","authenticated-orcid":false,"given":"Benjamin","family":"Batteux","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Amiens University Medical Center , Amiens ,","place":["France"]},{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie , Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pimentel","sequence":"additional","affiliation":[{"name":"AURA Paris , Saint Ouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-3213","authenticated-orcid":false,"given":"Agnes","family":"Ostertag","sequence":"additional","affiliation":[{"name":"INSERM U1132, Universit\u00e9 Paris-Cit\u00e9 and Department of Rheumatology, Lariboisi\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-7681","authenticated-orcid":false,"given":"Tilman B","family":"Dr\u00fceke","sequence":"additional","affiliation":[{"name":"CESP, Inserm U-1018, Universit\u00e9 Paris-Sud , Villejuif ,","place":["France"]},{"name":"Department of Biostatistics, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University, UVSQ) , Villejuif ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"INSERM U1132, Universit\u00e9 Paris-Cit\u00e9 and Department of Rheumatology, Lariboisi\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-1906","authenticated-orcid":false,"given":"Pablo Antonio Ure\u00f1a","family":"Torres","sequence":"additional","affiliation":[{"name":"AURA Paris , Saint Ouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026100605062470900_bib1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease\u2013mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"2026100605062470900_bib2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1359\/jbmr.090831","article-title":"Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease","volume":"25","author":"Bacchetta","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib3","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s00198-011-1890-9","article-title":"Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients","volume":"23","author":"Negri","year":"2012","journal-title":"Osteoporos Int"},{"key":"2026100605062470900_bib4","first-page":"437","article-title":"Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis","volume":"13","author":"Gerakis","year":"2000","journal-title":"J Nephrol"},{"key":"2026100605062470900_bib5","first-page":"122","article-title":"Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment","volume":"39","author":"Linderg\u00e5rd","year":"1985","journal-title":"Nephron"},{"key":"2026100605062470900_bib6","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2026100605062470900_bib7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"2026100605062470900_bib8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jbmr\/zjae021","article-title":"Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study","volume":"39","author":"Hsu","year":"2024","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfaf256","article-title":"A consensus statement on the management of vertebral fractures in CKD stages G4-G5D","volume":"41","author":"Fusaro","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026100605062470900_bib10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"key":"2026100605062470900_bib11","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100605062470900_bib12","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass","volume":"100","author":"Chen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100605062470900_bib13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-020-05391-3","article-title":"Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study","volume":"31","author":"Chen","year":"2020","journal-title":"Osteoporos Int"},{"key":"2026100605062470900_bib14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","article-title":"Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial","volume":"66","author":"Hiramatsu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026100605062470900_bib15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","article-title":"Denosumab for dialysis patients with osteoporosis: a cohort study","volume":"10","author":"Kunizawa","year":"2020","journal-title":"Sci Rep"},{"key":"2026100605062470900_bib16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib17","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/gfaa359","article-title":"Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study","volume":"36","author":"Hiramatsu","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026100605062470900_bib18","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1038\/s41598-022-12029-3","article-title":"Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients","volume":"12","author":"Hori","year":"2022","journal-title":"Sci Rep"},{"key":"2026100605062470900_bib19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5414\/CN110473","article-title":"Lower response to denosumab in diabetes patients on hemodialysis","volume":"97","author":"Han","year":"2022","journal-title":"Clin Nephrol"},{"key":"2026100605062470900_bib20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.kint.2018.02.013","article-title":"The authors reply","volume":"93","author":"Ure\u00f1a-Torres","year":"2018","journal-title":"Kidney Int"},{"key":"2026100605062470900_bib21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bone.2010.05.034","article-title":"Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT","volume":"47","author":"Burghardt","year":"2010","journal-title":"Bone"},{"key":"2026100605062470900_bib22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2026100605062470900_bib23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S8756-3282(99)00194-5","article-title":"Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach","volume":"25","author":"Hauge","year":"1999","journal-title":"Bone"},{"key":"2026100605062470900_bib25","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2026100605062470900_bib26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag033","article-title":"Bone turnover markers in the management of CKD-associated osteoporosis\u2014a European consensus","author":"Haarhaus","journal-title":"Nephrol Dial Transplant"},{"key":"2026100605062470900_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"2026100605062470900_bib28","first-page":"1","article-title":". KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2026100605062470900_bib29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100605062470900_bib30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normal kidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100605062470900_bib31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026100605062470900_bib32","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/jbmr.4421","article-title":"Retraction statement: bone mineral density predicts fractures in chronic kidney disease","volume":"36","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib33","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.bonr.2022.101169","article-title":"Bone mass measurement by DXA should be interpreted with caution in the CKD population with vascular calcification","volume":"16","author":"Campagnaro","year":"2022","journal-title":"Bone Reports"},{"key":"2026100605062470900_bib34","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/jcm13051462","article-title":"Effect of denosumab on bone health, vascular calcification, and health-related quality of life in hemodialysis patients with osteoporosis: a prospective observational study","volume":"13","author":"Kim","year":"2024","journal-title":"J Clin Med"},{"key":"2026100605062470900_bib35","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","article-title":"Long-term effect of denosumab on bone disease in patients with CKD","volume":"18","author":"Iseri","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100605062470900_bib36","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00198-017-3956-9","article-title":"Biopsy vs. peripheral computed tomography to assess bone disease in CKD patients on dialysis: differences and similarities","volume":"28","author":"Marques","year":"2017","journal-title":"Osteoporos Int"},{"key":"2026100605062470900_bib37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jbmr.4538","article-title":"Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years","volume":"37","author":"Farlay","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib38","first-page":"zjaf006","article-title":"Time-lapse HR-pQCT reliably assesses and monitors local bone turnover in patients with chronic kidney disease","author":"Zhou","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026100605062470900_bib39","doi-asserted-by":"publisher","first-page":"e1534","DOI":"10.1210\/clinem\/dgad724","article-title":"Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis","volume":"109","author":"Bioletto","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100605062470900_bib40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00223-020-00779-z","article-title":"Bone fragility fractures in CKD patients","volume":"108","author":"Pimentel","year":"2021","journal-title":"Calcif Tissue Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag182\/71281347\/sfag182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag182\/71281347\/sfag182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag182\/71281347\/sfag182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:06:34Z","timestamp":1791277594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag182\/8824267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag182","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,21]]},"article-number":"sfag182"}}